What is it? This is not your father's nebulizer. A new range of materials--and nanomaterials--are being developed for pulminary delivery via aerosols, metered dose inhaler systems, dry powder inhalers or nebulizers. Research into lung delivery is driven by the potential for successful gene therapy for respiratory diseases such as cystic fibrosis.
Why is it groundbreaking? Aerosol delivery offers alternative technologies to meds going off patent. According to a recent report in in-PharmaTechnologist, Big Pharma is biting. Recently, "three of the world's largest industry companies" expressed interest in using a platform developed by one company, Stirling, to create inhalable formulations of their drugs. Studies are ongoing on the benefits of aerosol vs. oral for treatment of TB.
Who's working on it?
- Stirling is one of many companies offering alternative delivery technologies to meds going off patent. What Stirling offers is its high density aerosol technology, which promises to provide the same efficacy as drugs taken orally, but with far less active drug content, according to the company. That, the company adds, means fewer side effects. Report
- Savara Pharmaceuticals, based in Austin, Texas, has caught the attention of investors for its nanoscale powders--called NanoClusters--to take the place of propellants for delivery via oral pulmonary or nasal routes. Report